⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of HighField Biopharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
HighField Biopharmaceuticals
↗Hangzhou, China
HighField Biopharmaceuticals is a clinical-stage biotechnology company specializing in the development of novel lipid-based therapeutics. The company focuses on disrupting existing immuno-oncology technologies through its proprietary platforms, including immunoliposomes and lipid nanoparticles (LNPs) for gene delivery.
Their pipeline targets solid tumors, diabetes, and other complex diseases. HighField operates its own research and development center and a GMP-compliant production facility, positioning itself as an innovator in drug delivery systems that aim to improve the safety and efficacy of cancer treatments compared to traditional modalities like CAR-T or bispecific antibodies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Ownership:private
Status:operating
FUNDING
Stage:Private
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1/2
Modalities:Liposomes, mRNA, ADC, LNP
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
Competitors:CAR-T therapy developers, Bispecific antibody developers
LEADERSHIP
Key Executives:
Yuhong Xu - CEO and Scientific Founder
Donald Wyatt - Chief Business Officer
Scientific Founders:Yuhong Xu
LINKS
Website:hf-biopharm.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with HighField Biopharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.